Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
- This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
- Publisher copy:
- American journal of cardiology
- Publication date:
- Pubs id:
- Local pid:
- Source identifiers:
- Deposit date:
- Copyright date:
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record